Nuvo is primarily focused on the R&D of drug products delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10.
Nuvo’s lead product is Pennsaid, a topical non-steroidal anti-inflammatory drug (NSAID), which is sold in Canada, the US and several European countries.
Pennsaid was approved for marketing in the US by the United States Food and Drug Administration on 4 November 2009 and is being sold throughout the US by Nuvo’s licensing partner, Mallinckrodt, a Covidien company.
Nuvo intends to create a portfolio of products through internal R&D and by in-licensing and acquisition.
Nuvo Research chairman and co-CEO Dan Chicoine said that the research grants recognise their capability to create topical and transdermal formulations that have the potential to have an impact on patient care and to become part of their product development pipeline.